about
Peptide-Based Treatment: A Promising Cancer TherapyPrognostic and Predictive Value of DAMPs and DAMP-Associated Processes in CancerVaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Chloroquine and hydroxychloroquine for cancer therapyTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsTrial watch: IDO inhibitors in cancer therapyTrial Watch:: Oncolytic viruses for cancer therapyTrial watch: Dendritic cell-based anticancer therapyCancer vaccinesTrial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapyTrial Watch-Immunostimulation with cytokines in cancer therapyTrial Watch: Proteasomal inhibitors for anticancer therapyTrial watch: Immunostimulatory cytokines in cancer therapy.Current status of cancer immunotherapyTrial Watch: Peptide-based anticancer vaccines.Novel immune checkpoint blocker approved for the treatment of advanced melanomaClassification of current anticancer immunotherapiesPDL1 expression is an independent prognostic factor in localized GIST.Trial watch: Naked and vectored DNA-based anticancer vaccinesOverexpressed oncogenic tumor-self antigensPhase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer.Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapyExtracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies.Particulate inorganic adjuvants: recent developments and future outlook.Immunotherapy of melanoma: present options and future promises.Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Glioblastoma: molecular pathways, stem cells and therapeutic targets.Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?Gold nanoparticles and vaccine development.Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.E2F-1 promotes DAPK2-induced anti-tumor immunity of gastric cancer cells by targeting miR-34a.Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma.Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.HLA class I as a predictor of clinical prognosis and CTL infiltration as a predictor of chemosensitivity in ovarian cancer.Trial Watch: DNA vaccines for cancer therapy.Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine.
P2860
Q26777032-2D325ED5-C34E-4F90-BDDC-AC79F326773BQ26795466-C8ED8734-8E8D-4A53-9CA8-A074DA078B94Q26796314-16789B55-DB31-4D80-97B5-5F717C440CD3Q26827797-BFB421E3-F382-4776-8436-1715DA31E1CBQ26993238-82BC33B6-8537-4E2C-87FB-FA88C50694A6Q26996518-4165E47A-179D-4627-9F3A-2F31A72E7D79Q27006866-50AAC64D-E460-4FF3-87C9-1DFEAB593326Q27021951-D857D20F-BB37-4F3C-B66B-BC1B01597A30Q27024047-D2829F1E-203A-44BC-84E9-85798D73A3FCQ27024438-88A6E2B9-F0EB-4B5F-8C41-1FB5B51D0CD4Q28067939-313531A7-6B6F-4C47-BEA7-52B5A4219CF9Q28078725-A0239E5A-88CE-4E8A-8BD6-55E037993A97Q28082910-E2263D79-289C-4059-948E-6984046305B8Q33880165-FBF77288-B351-4D15-BB3F-B76720675EDEQ33955720-4CA882CB-AADB-425C-93C8-C3F9187EC20DQ34483345-E3A4D0C7-BEA5-47FA-8259-D3D928E8A23DQ34936394-2D07AEB4-D43E-40C9-B16B-41A1DF869F85Q35149637-F462FBE6-2F7F-4A90-AC83-71694CF30E81Q35798839-9E280F54-675B-479D-9AB9-8BD3269FDA99Q35798986-3A5EAF93-C687-46AA-8618-A363CDAA47D6Q35886756-1B303688-8D64-43D6-A449-86DA0A8B29F7Q35968018-4CBB569C-96F0-4139-ABD3-A3A79AF9DFCEQ36801213-8D397563-0479-4325-899A-450BC4236C74Q37652790-C2C60BAE-138B-47B9-AB45-7F2357F27AC9Q38226527-78951FD8-4198-4D70-B6CC-0D0184FDA086Q38286377-733FCB2D-882B-4850-B2EA-7F6DB30CB8FAQ38318683-180A4294-7AE7-427D-B2E4-2A29FB38F26CQ38364462-557DFF12-218A-441E-98E6-CAFBA467135DQ38393328-88205F81-4D7E-4D26-83A6-8B19CD4A5438Q38447992-C6A2F0CE-6A37-48B4-8553-50F16268A39CQ38543673-E26F6CEB-57DD-4205-96FF-2F9968C548D1Q38952962-42EF0B0E-E6DD-4DB8-A51B-A4866423420AQ39321877-5A9E829F-C24C-429D-896E-F39979AD86DFQ40438006-AE2D9E07-DDFE-4FCD-A1D1-524491FBC900Q41591613-A3D79B3F-E14B-4E65-9ABB-5402E4FF0D41Q41592674-91EAE82B-9558-4661-8FB8-AB979A53748AQ42552005-43A73E0D-86A9-455E-A4FC-7D5EE39EFF04Q42558833-05035F58-A79C-446F-90DD-C007FF448915Q42702234-A6C77AF6-CE6C-4D6C-906E-BEFFC2C93BBAQ43032177-90DB1F94-F000-4FB3-8659-587F5B0EC082
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Trial Watch: Peptide vaccines in cancer therapy.
@en
Trial Watch: Peptide vaccines in cancer therapy.
@nl
type
label
Trial Watch: Peptide vaccines in cancer therapy.
@en
Trial Watch: Peptide vaccines in cancer therapy.
@nl
prefLabel
Trial Watch: Peptide vaccines in cancer therapy.
@en
Trial Watch: Peptide vaccines in cancer therapy.
@nl
P2860
P50
P356
P1433
P1476
Trial Watch: Peptide vaccines in cancer therapy.
@en
P2093
Alexander Eggermont
Catherine Sautès-Fridman
P2860
P304
P356
10.4161/ONCI.26621
P50
P577
2013-11-04T00:00:00Z